A drug pair tried when lung cancer spread to the lining of the brain
Original title: Multimodality salvage treatment incorporating ivonescimab plus chemotherapy for EGFR-mutated NSCLC with leptomeningeal metastases after dose-escalated third-generation EGFR-TKI failure: a retrospective study.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
Doctors only looked back at records of people already treated, so this is not proven as a treatment.
The short version
Doctors looked back at 33 people whose lung cancer had spread to the lining of the brain and spinal cord, and who had run out of other options.
What was studied. This was a look back at records at one hospital. 33 adults with EGFR-mutated lung cancer and cancer in the lining of the brain were given a drug called ivonescimab along with chemotherapy. All of them had gotten worse on a higher dose of an EGFR pill first.
What they found. Half of the group lived longer than 8.54 months after starting the drugs. Of 29 people checked for a response, 6 had the cancer in the lining shrink. Serious side effects happened in 14 of 31 people, most often low blood counts. No one stopped ivonescimab for good because of side effects.
What this means, and what it doesn't
What it could mean: For people who have very few choices left, this pair of drugs may be worth asking a doctor about. Most people in this group were already quite sick and had tried many treatments. Some got more time, but side effects were common.
What it doesn't mean: This does not mean the drug pair works. Doctors only read old records at one hospital. There was no comparison group, so we cannot know what would have happened with other care. 33 people is a very small number. This is early, real world information. It is not standard care, and it is not a cure.
Source: PubMed, October 5, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.